The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $64.41

Today's change0.00 0.00%
Updated August 31 4:03 PM EDT. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $64.41

Today's change0.00 0.00%
Updated August 31 4:03 PM EDT. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd closed at (U.S.)$64.41.

Over the last five days, shares are unchanged, but have gained 12.00% over the last year to date. This security has outperformed the S&P 500 by 24.20% during the last year.

Key company metrics

  • Open(U.S.) $64.57
  • Previous close(U.S.) $64.41
  • High(U.S.) $65.29
  • Low(U.S.) $64.22
  • Bid / Ask-- / --
  • YTD % change+12.00%
  • Volume2,235,709
  • Average volume (10-day)5,266,590
  • Average volume (1-month)4,345,720
  • Average volume (3-month)4,739,872
  • 52-week range(U.S.) $47.36 to (U.S.) $72.31
  • Beta0.73
  • Trailing P/E21.70×
  • P/E 1 year forward11.95×
  • Forward PEG1.99×
  • Indicated annual dividend(U.S.) $1.69
  • Dividend yield2.62%
  • Trailing EPS(U.S.) $2.97
Updated August 31 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.59%

Based on its net profit margin of 12.59%, Teva Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue4,9664,9825,1685,058
Total other revenue--------
Total revenue4,9664,9825,1685,058
Gross profit2,9022,8362,8892,809
Total cost of revenue2,0642,1462,2792,249
Total operating expense4,3044,2334,2263,946
Selling / general / administrative1,1771,2211,3261,240
Research & development386332379412
Depreciation / amortization88--3
Interest expense (income), net operating--------
Unusual expense (income)66952624242
Other operating expenses, total--------
Operating income6627499421,112
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax6215578721,028
Income after tax533453686868
Income tax, total88104186160
Net income539446687876
Total adjustments to net income------0
Net income before extra. items539446687876
Minority interest02-713
Equity in affiliates6-98-5
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items539446687876
Inc. avail. to common incl. extra. items539446687876
Diluted net income539447689878
Dilution adjustment0122
Diluted weighted average shares859859861861
Diluted EPS excluding extraordinary itemsvalue per share0.630.520.801.02
Dividends per sharevalue per share0.340.350.320.34
Diluted normalized EPSvalue per share1.301.021.021.06